Lilly puts up to $1B in obesity drug discovery deal; Novartis to spend $200M in further bid to boost radiopharma manufacturing; Top takeaways from BioMarin’s investor day.
Five things for pharma marketers to know for Wednesday morning
MM+M hires Jameson Fleming as its next editor-in-chief; Hispanic voters give Vice President Kamala Harris an edge over former President Donald Trump on healthcare; A booming market for weight-loss drugs puts investors’ focus firmly on the pharmaceutical sector.
Novo Nordisk’s GLP-1 Wegovy cuts the chances of patients dying from COVID; Dermavant’s storytelling platform turns kids’ eczema woes into wins; FDA expands approval of Emergent’s smallpox vaccine for mpox.
Rx Rundown: Illumina, The WHO, Navigator Medicines and more
Pfizer will work with the Flagship-funded Quotient Therapeutics to conduct research that will inform drug development for cardiovascular and renal diseases.
AI Deciphered: Discovering the Potential for Marketers and Communicators